Targeting effector memory T-cells with Kv1.3 blockers

Heike Wulff, M. Pennington

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

After initially being pursued for general immunosuppression, the voltage-gated potassium channel Kv1.3 has more recently emerged as an attractive pharmacological target for the selective suppression of CCR7- effector memory T-cells in T-cell mediated autoimmune diseases such as multiple sclerosis, type 1 diabetes, rheumatoid arthritis and psoriasis. This article gives a brief summary of the role of Kv1.3 in autoimmune diseases, reviews the progress made in both developing peptidic and small-molecule inhibitors for this challenging target, and in validating Kv1.3 as a target for the treatment of autoimmune diseases.

Original languageEnglish (US)
Pages (from-to)438-445
Number of pages8
JournalCurrent Opinion in Drug Discovery and Development
Volume10
Issue number4
StatePublished - Jul 2007

Fingerprint

Autoimmune Diseases
T-Lymphocytes
Voltage-Gated Potassium Channels
Type 1 Diabetes Mellitus
Psoriasis
Immunosuppression
Multiple Sclerosis
Rheumatoid Arthritis
Pharmacology
Therapeutics

Keywords

  • Autoimmune disease
  • Effector memory T-cell
  • Immunosuppression
  • Kv1.3
  • Multiple sclerosis
  • Peptide toxin
  • Psoriasis
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Targeting effector memory T-cells with Kv1.3 blockers. / Wulff, Heike; Pennington, M.

In: Current Opinion in Drug Discovery and Development, Vol. 10, No. 4, 07.2007, p. 438-445.

Research output: Contribution to journalArticle

@article{d657684e2ce843ac8f9956b85aca6cfd,
title = "Targeting effector memory T-cells with Kv1.3 blockers",
abstract = "After initially being pursued for general immunosuppression, the voltage-gated potassium channel Kv1.3 has more recently emerged as an attractive pharmacological target for the selective suppression of CCR7- effector memory T-cells in T-cell mediated autoimmune diseases such as multiple sclerosis, type 1 diabetes, rheumatoid arthritis and psoriasis. This article gives a brief summary of the role of Kv1.3 in autoimmune diseases, reviews the progress made in both developing peptidic and small-molecule inhibitors for this challenging target, and in validating Kv1.3 as a target for the treatment of autoimmune diseases.",
keywords = "Autoimmune disease, Effector memory T-cell, Immunosuppression, Kv1.3, Multiple sclerosis, Peptide toxin, Psoriasis, Rheumatoid arthritis",
author = "Heike Wulff and M. Pennington",
year = "2007",
month = "7",
language = "English (US)",
volume = "10",
pages = "438--445",
journal = "Current Opinion in Drug Discovery and Development",
issn = "1367-6733",
publisher = "Current Drugs Ltd.",
number = "4",

}

TY - JOUR

T1 - Targeting effector memory T-cells with Kv1.3 blockers

AU - Wulff, Heike

AU - Pennington, M.

PY - 2007/7

Y1 - 2007/7

N2 - After initially being pursued for general immunosuppression, the voltage-gated potassium channel Kv1.3 has more recently emerged as an attractive pharmacological target for the selective suppression of CCR7- effector memory T-cells in T-cell mediated autoimmune diseases such as multiple sclerosis, type 1 diabetes, rheumatoid arthritis and psoriasis. This article gives a brief summary of the role of Kv1.3 in autoimmune diseases, reviews the progress made in both developing peptidic and small-molecule inhibitors for this challenging target, and in validating Kv1.3 as a target for the treatment of autoimmune diseases.

AB - After initially being pursued for general immunosuppression, the voltage-gated potassium channel Kv1.3 has more recently emerged as an attractive pharmacological target for the selective suppression of CCR7- effector memory T-cells in T-cell mediated autoimmune diseases such as multiple sclerosis, type 1 diabetes, rheumatoid arthritis and psoriasis. This article gives a brief summary of the role of Kv1.3 in autoimmune diseases, reviews the progress made in both developing peptidic and small-molecule inhibitors for this challenging target, and in validating Kv1.3 as a target for the treatment of autoimmune diseases.

KW - Autoimmune disease

KW - Effector memory T-cell

KW - Immunosuppression

KW - Kv1.3

KW - Multiple sclerosis

KW - Peptide toxin

KW - Psoriasis

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=34447625549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447625549&partnerID=8YFLogxK

M3 - Article

C2 - 17659485

AN - SCOPUS:34447625549

VL - 10

SP - 438

EP - 445

JO - Current Opinion in Drug Discovery and Development

JF - Current Opinion in Drug Discovery and Development

SN - 1367-6733

IS - 4

ER -